An Open-Label, Randomised Phase 1b/2 Study Of PF-04691502 In Combination With Letrozole Compared With Letrozole Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Early Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs PF 4691502 (Primary) ; Letrozole
- Indications Advanced breast cancer; Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 29 Nov 2012 Planned End Date changed from 1 Apr 2014 to 1 May 2013 as reported by ClinicalTrials.gov.
- 06 Sep 2012 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.